- Home
- OUST vs TECX Comparison
OUST vs TECX Comparison
Compare OUST & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUST
- TECX
- Stock Information
- Founded
- OUST 2015
- TECX 2019
- Country
- OUST United States
- TECX United States
- Employees
- OUST N/A
- TECX N/A
- Industry
- OUST Industrial Machinery/Components
- TECX
- Sector
- OUST Technology
- TECX
- Exchange
- OUST Nasdaq
- TECX Nasdaq
- Market Cap
- OUST 1.1B
- TECX 334.4M
- IPO Year
- OUST N/A
- TECX 2018
- Fundamental
- Price
- OUST $22.76
- TECX $21.69
- Analyst Decision
- OUST Strong Buy
- TECX Buy
- Analyst Count
- OUST 7
- TECX 6
- Target Price
- OUST $14.33
- TECX $78.67
- AVG Volume (30 Days)
- OUST 4.8M
- TECX 241.7K
- Earning Date
- OUST 08-12-2025
- TECX 08-13-2025
- Dividend Yield
- OUST N/A
- TECX N/A
- EPS Growth
- OUST N/A
- TECX N/A
- EPS
- OUST N/A
- TECX N/A
- Revenue
- OUST $117,789,000.00
- TECX N/A
- Revenue This Year
- OUST $32.34
- TECX N/A
- Revenue Next Year
- OUST $36.11
- TECX N/A
- P/E Ratio
- OUST N/A
- TECX N/A
- Revenue Growth
- OUST 28.04
- TECX N/A
- 52 Week Low
- OUST $5.84
- TECX $13.70
- 52 Week High
- OUST $26.07
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- OUST 60.41
- TECX 51.82
- Support Level
- OUST $20.32
- TECX $19.13
- Resistance Level
- OUST $26.07
- TECX $21.46
- Average True Range (ATR)
- OUST 1.91
- TECX 1.27
- MACD
- OUST -0.31
- TECX -0.00
- Stochastic Oscillator
- OUST 48.41
- TECX 70.50
About OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.